Megan Frisk, PhD

Dr. Megan Frisk is the Chief Strategy Officer at Alloy Therapeutics. Previously, she was the Chief of Staff (Acting) and the Director for International Affairs at the Advanced Research Projects Agency for Health (ARPA-H). Before that she served at the U.S. Department of State, where she was Senior Advisor in the Office of the Special Envoy for Critical & Emerging Technology and, prior to that, a member of the Secretary’s Policy Planning Staff. From 2021-2022, Megan served as Director for Biotechnology Risk and Biological Weapons Nonproliferation at the White House National Security Council (NSC), where she focused on bioeconomy, international biosafety and biosecurity, and BW nonproliferation policy. Prior to her time at the White House, she was a foreign affairs officer in the Office of Science and Technology Cooperation, Bureau of Oceans and International Environmental and Scientific Affairs, managing bilateral S&T relations with countries in Western Europe, research integrity and security policy, and the foreign policy implications of advanced and emerging biotechnologies. Megan joined the State Department in 2016 as an American Association for the Advancement of Science (AAAS) S&T Policy Fellow in the Office of the Science and Technology Adviser to the Secretary, where she focused on emerging technologies and multilateral S&T. Before entering the U.S. Government, Megan was a senior editor at Science Translational Medicine – in the Science family of research journals – and the editor of Trends in Biotechnology, a review journal published by Cell Press. Megan obtained a BS in biochemistry from the University of Virginia and a PhD in analytical chemistry from the University of Wisconsin-Madison.